Advisers to the Food and Drug Administration (FDA) on June 5 advised the regulatory agency to direct vaccine manufacturers to produce new COVID-19 vaccines targeting the JN.1 virus variant.
Advisers voted 16–0 to recommend monovalent updated vaccines, after being barred from considering bivalent formulations. They then made clear that the updated vaccines should target JN.1, as opposed to one of the dominant or soon-to-be dominant strains.
